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In 2010 South Africa revised its HIV treatment guidelines to allow the initiation and manage-
ment of patients on antiretroviral therapy (ART) by nurses, rather than solely doctors, under
a program called NIMART (Nurse Initiated and Managed Antiretroviral Therapy). We com-
pared the outcomes and costs of NIMART between the two major public sector HIV treat-
ment delivery models in use in South Africa today, primary health clinics and hospital-based
HIV clinics.
Methods and findings
The study was conducted at one hospital-based outpatient HIV clinic and one primary health
clinic (PHC) in Gauteng Province. A retrospective cohort of adult patients initiated on ART at
the PHC was propensity-score matched to patients initiated at the hospital outpatient clinic.
Each patient was assigned a 12-month outcome of alive and in care or died/lost to follow up.
Costs were estimated from the provider perspective for the 12 months after ART initiation.
The proportion of patients alive and in care at 12 months did not differ between the PHC
(76.5%) and the hospital-based site (74.2%). The average annual cost per patient alive and
in care at 12 months after ART initiation was significantly lower at the PHC (US$238) than at
the hospital outpatient clinic (US$428).
Conclusions
Initiating and managing ART patients at PHCs under NIMART is producing equally good
outcomes as hospital-based HIV clinic care at much lower cost. Evolution of hospital-based
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clinics into referral facilities that serve complicated patients, while investing most program
expansion resources into PHCs, may be a preferred strategy for achieving treatment cover-
age targets.
Introduction
With over 2.6 million people on HIV treatment, South Africa has had unprecedented success
in rolling out its public sector antiretroviral therapy (ART) program[1]. Despite this success,
further expansion to 5.7 million patients on treatment by 2018/2019 [2] will be needed for
South Africa to reach the “90-90-90” targets established by the World Health Organization [3],
and current budgetary resources are not sufficient [2]. Expanding access to ART at the lowest
possible cost is therefore essential, for South Africa and for many other countries facing similar
challenges.
When the South African national antiretroviral therapy (ART) program began in 2004, it
relied primarily on hospital-based HIV clinics with services delivered by doctors [4]. In 2010,
in the face of increasing demand for care and limited personnel, South Africa revised its treat-
ment guidelines to allow the initiation and management of patients on ART by nurses at both
hospitals and primary health clinics (PHCs) [5, 6] under a program known as Nurse Initiated
and Managed Antiretroviral Therapy (NIMART).
NIMART shifted the focus of the South African treatment program from doctors to nurses
and from hospitals to PHCs, increasing the number of accredited ART delivery facilities sites
from 496 to 4333 [7]. With the advent of NIMART, South Africa now has two major public
sector ART delivery models: centralized, hospital-based HIV outpatient clinics, which serve
roughly 12% of patients; and decentralized, full service, primary health clinics, which serve
about 85% (authors’ data). Both decentralization and task shifting have been shown to generate
health outcomes equivalent to or better than centralized, doctor-led care [8–12]. A recent
Cochrane review concluded that there was moderate evidence showing that task shifting for
HIV management did not decrease the quality of care and, for patients who were initiated on
ART by nurses, may reduce patient loss to follow-up [13].
While several studies have examined outcomes of task shifting and decentralization in
South Africa [14–24], few have included both ART initiation and management by nurses in
routine public sector care without external resources. Neither of the two available cost esti-
mates, moreover, reflect routine NIMART implementation [17, 25]. There is also no evidence
of how NIMART fares at different levels of the public health system; for example primary
health clinic relative to traditional hospital-based HIV outpatient clinic, under the normal con-
ditions and constraints of a typical public sector setting. We used routinely collected patient
data and actual resource utilization and cost records to evaluate the outcomes and costs of
NIMART at a hospital outpatient HIV clinic compared to primary health clinic and provide
evidence to guide future program expansion.
Methods
Study sites
The study was conducted at one hospital-based outpatient HIV treatment clinic and one pri-
mary health clinic. Both sites are situated in the same municipality (pop. 360,000) in West
Rand District of Gauteng Province, South Africa. The district was one of the early adopters of
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NIMART across all its facilities. The two sites are seven kilometers apart and serve similar
populations.
The hospital-based HIV clinic is a large regional hospital hereafter referred to as the ‘HIV
outpatient clinic’. As of March 2014 it had 4,396 patients actively on ART and saw an average
of 1,956 ART patients per month. It originally provided ART initiation and management by
doctors, with nurse support for screening and monitoring. With the introduction of NIMART,
responsibility for these services was progressively shifted to nurses. During the study period,
the HIV outpatient clinic had one dedicated, full time doctor and sixteen nurses (including
enrolled nurse assistants and managers).
The primary health clinic (PHC), hereafter referred to as “the PHC”, had as of March 2014
1,958 patients actively on ART and saw approximately of 884 HIV patients for ART pickup in
March 2014, which was roughly 11% of the patient load. As of January 2012, HIV was fully
integrated into general chronic disease care at the site. During the study period (2012) it had
fifteen clinical staff (nurses and a doctor) serving all patients seeking care at the clinic for all
conditions.
Sample selection and matching
We constructed a retrospective cohort of adult (18 years) patients initiated on ART at the
PHC and matched them to patients initiated at the HIV outpatient clinic. To be included in
the cohort, patients had to have at least 15 months of potential follow up as of the date of data
collection, not have transferred to another site during their first year after initiation, having
initiated after 1 January 2011 (NIMART policy in place) and have a complete patient record
available for review. Data collection commenced on 15 January 2014 at the PHC and 1 March
2014 at the HIV outpatient clinic, resulting in the cohorts including patients initiated prior to
15 October 2013 and 1 December 2013 at the PHC and HIV outpatient clinic respectively. At
the PHC we enrolled the first 260 patients based on date of initiation who met these inclusion
criteria. These patients were then matched to hospital outpatient clinic patients 1:3 on gender,
age at initiation (18–30, 31–40, 41–50,>50 years), baseline ART regimen, and baseline CD4
count (0–100, 101–200, 201–350, 350 cells/mm3). Viral load is not routinely performed at initi-
ation and could therefore not be included as a matching variable. We used propensity score
matching without replacement [26] using the Vmatch macro in SAS [27] to identify a compar-
ison population from among all patients in the HIV outpatient clinic database who initiated
ART after 1 January 2011 and met the study inclusion criteria.
Outcomes data and analysis
Clinical data were collected from paper files and the national electronic HIV register (Tier.net)
at the primary health clinic and from a separate electronic patient record (TherapyEdge ™) at
the HIV outpatient clinic. Study data collectors extracted data from the paper files at the pri-
mary health clinic and site staff routinely captured the data found in Tier.net and the Therapy
Edge datasets. All three of these sources contained only routinely collected data. Fields col-
lected for the first 12 months following ART initiation for each patient included baseline CD4
count, date of ART initiation, resource usage (visits, laboratory tests, drugs), and outcome at
12 months. CD4 count and viral load results up to 15 months were also collected to assign
12-month outcomes. All patient level data were collected using a study specific database
designed and managed in CS Pro (United States Census Bureau, 2014).
Each patient was assigned a single primary, 12-month outcome of either “alive and in care”
or “died / lost to follow-up (LTFU)”. If a patient died before 12 months or was >3 months late
for their last scheduled visit within the 12-month follow up period (lost to follow-up) then the
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patient was assigned to the outcome “died / LTFU”. All other patients were considered “alive
and in care”. Secondary outcomes based on virologic and immunologic status were also
assigned. Patients with a viral load 1,000 copies/mm3 between 9–15 months after treatment
initiation were classified as “unsuppressed viral load”. Patients with a CD4 count in month
9–15 showing a decrease of>30% from the highest recorded CD4 count between 0–12 months
or below the CD4 count at ART initiation were classified as “immunologic failure”. For labora-
tory results we used the test result reported between 9 and 15 months that was closest to the
12-month endpoint. We then compared the primary and secondary outcomes over the first 12
months of treatment between sites using crude risk ratios with corresponding 95% confidence
intervals. Data cleaning, analysis of the patient level database and creation of the resource utili-
zation database were done using SAS software, version 9.3 (SAS Institute, 2012).
Through sensitivity analysis, we investigated the effect of missing paper files excluded at the
PHC (no patients were excluded at the HIV outpatient clinic because of missing files). Data on
age, gender, baseline CD4 count, and 12-month primary outcome were collected from Tier.
net for patients with missing files, where possible. In the sensitivity analysis, all primary health
clinic patients were then matched on age, gender and baseline CD4 count to the hospital out-
patient clinic and outcomes were compared. The data available on Tier.net were not sufficient
to extract resource utilization and calculate costs. The analytic cohort therefore only included
patients who had a paper patient file at the primary health clinic.
Cost data and analysis
Costs were estimated from the provider perspective for the 12 months after ART initiation
using standard costing methods, as outlined in Table 1 and described in previous publications
[17, 28]. Resources incurring costs included drugs, diagnostics, clinical staff, space, equipment
and other shared services (i.e. other staff, utilities, etc.). Variable resource usage was deter-
mined from patient records; utilization of fixed resources, such as space and shared services,
was estimated from site records. The quantity of each resource used by each patient was then
multiplied by the associated unit cost to determine a total cost per patient. All unit costs were
in 2014 South African Rand (ZAR) or adjusted to 2014 and reported costs were converted to
United States Dollar (USD) at the average exchange rate prevailing during 2014 of 10.83:1
(ZAR:USD). Average resource utilization per patient year is presented by site; average cost per
patient is presented by site, cost category, and primary outcome with a 95% confidence inter-
val, where appropriate. The resource utilization and cost analysis were done in Excel 2013
(Microsoft).
The study protocol was reviewed by the Institutional Review Boards of the University of
Witwatersrand and Boston University, who approved the collection of the data without
informed consent and the use of an anonymous analytic dataset.
Results
Sample characteristics
Sample selection is outlined in S1 Fig. A sample of 260 patients was selected from the primary
health clinic, of whom 60 were excluded (55 missing files, 3 missing baseline CD4 count, 2
transferred within 12 months of initiating). The final analytic data set therefore included 200
patients from the primary health clinic matched with 600 patients from the HIV outpatient
clinic. The patients excluded from the PHC sample because of missing data were similar to
those included in terms of age and gender but had a slightly higher baseline median (IQR)
CD4 count (208 cells/mm3 (122–269 cells/mm3)) than those included (162 cells/mm3 (87–257
cells/mm3)).
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Characteristics of the sample are described in Table 2. The median age was 34 years (IQR:
28–41 years) and median CD4 count 151 cells/mm3 (IQR: 69.5–239.5 cells/mm3); two thirds
were female. Most patients were initiated on a baseline regimen of lamivudine and tenofovir
with either efavirenz (83%) or nevirapine (8%). There were no important differences in sample
characteristics between the two sites.
Outcomes
The primary and secondary outcomes are presented in Table 3. The majority of patients at
both the HIV outpatient clinic (72%) and the PHC (82%) were reported to be alive and in care
at 12 months. Being a patient at the primary health clinic appeared to be somewhat protective
against death or loss to follow-up (RR: 0.66, 95% CI: 0.48–0.91). However, as S1 Fig. 1 indi-
cates, 55 paper patient files from the original sample selected for the PHC were missing and
were excluded from the primary analysis. Those patients with missing paper files (55) were
identified on the electronic patient database (Tier.net); of these patients, two were excluded
because they had transferred to other facilities and six were excluded because they had no base-
line CD4 count. The remaining 47 were included in a sensitivity analysis, where we considered
the impact of the missing files on patient outcomes at the PHC. We found that patients with
missing files were more likely to be lost to follow up or dead than were those included in the
main analysis. When the outcomes of the patients with missing files were included in the anal-
ysis, the difference between the sites in the proportion of patients not in care disappeared (RR:
Table 1. Methods for estimating costs.
Type of cost Method for estimating cost
VARIABLE COSTS (RESOURCES RECORDED IN PATIENT MEDICAL RECORDS)
Drugs, diagnostics, and other services reported
in individual subjects’ medical records
Unit cost obtained from suppliers or site and multiplied by
actual resource usage for each patient.
Staffing (visits) The specific staff cadres providing service for each patient
visit is not recorded in patient files. A uniform staffing cost
is estimated per patient visit at each site based on total
staff cost divided by the total visits during the period. The
actual number of visits made by the patient is then
multiplied by this cost.
FIXED COSTS (RESOURCES USED FOR CLINIC OPERATION, NOT ALLOCATED TO INDIVIDUAL
PATIENTS)
Buildings and utilities The space of the building was measured and an average
rental cost per square metre obtained from the property
market for commercial properties in the area was applied.
Utilities were not measured at the study sites and so an
estimated utility cost per square metre was determined
based on a property with basic utility demands (i.e. basic
electronic equipment and lighting, air-conditioning, water
for cleaning and sanitation).
Equipment All computer and related equipment was inventoried and
costed using the appropriate unit costs and expected
working life. Basic furnishings and equipment were costed
by including a 10% markup on the rental.
Supplies This included all non-drug and non-diagnostic related
supplies (i.e. gloves, paper, pens). Supply usage was not
well recorded at the facilities. The available information
was captured and an estimated cost was calculated per
month per patient visit. The same supply cost per visit
was applied to both sites in order to prevent the costs
being biased towards a site with incomplete supply
records.
doi:10.1371/journal.pone.0168118.t001
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0.91, 95% CI: 0.71–1.18). There was no difference between the sites in outcomes stratified by
baseline CD4 count. We also found no difference in unsuppressed viral load or immunologic
failure rates between the sites for those patients who had the necessary diagnostics reported in
their files (238/800 and 205/800 for viral load and CD4 count, respectively). We thus conclude
that after taking into account the effect of the missing files, the primary outcomes were compa-
rable between the sites.
Resource utilization and costs
Table 4 compares baseline CD4 counts, duration in care, and utilization of clinic visits and lab-
oratory tests by site and outcome category. Not surprisingly, at both sites patients alive and in
care at 12 months had a higher median baseline CD4 count than those not in care. More sur-
prisingly, patients who did not remain in care for 12 months at the PHC spent almost twice as
much time in care (7.5 months) as did patients at the HIV outpatient clinic (3.7 months).
Resource utilization by site and outcome reflects these differences in duration of care. In gen-
eral, resource utilization was slightly higher at the PHC than at the HIV outpatient clinic, pri-
marily because patients at the PHC who ultimately died or were lost to follow up remained in
care for an average of nearly four more months, long enough to make at least one more clinic
visit and undergo an additional set of laboratory tests. For patients who did remain in care, dif-
ferences between the sites were modest, with the PHC reporting slightly fewer clinic visits and
slightly more laboratory tests.
Table 2. Baseline characteristics at HIV treatment initiation.
Characteristics Total HIV Outpatient Clinic Primary Health Clinic
n = 800 n = 600 n = 200
BASELINE CHARACTERISTICS AT HIV TREATMENT INITIATION1
Gender, n (%)
Male 275 (34.4) 206 (34.3) 69 (34.5)
Female 525 (65.6) 394 (65.7) 131 (65.5)
Age, n (%)
18–30 273 (34.1) 206 (34.3) 67 (33.5)
31–40 324 (40.5) 233 (38.8) 91 (45.5)
41–50 141 (17.6) 112 (18.7) 29 (14.5)
>50 62 (7.8) 49 (8.2) 13 (6.5)
Age, median (IQR) 34 (28–41) 34 (29–39) 34 (28–41)
Baseline ART Regimen, n (%)
3TC-TDF-EFV 663 (82.9) 506 (84.3) 157 (78.5)
3TC-TDF-NVP 62 (7.8) 33 (5.5) 29 (14.5)
Other 75 (9.4) 61 (10.2) 14 (7.0)
Baseline CD4 Count, n (%)
100 cells/mm3 248 (31.0) 192 (32.0) 56 (28.0)
101–200 cells/mm3 263 (32.9) 202 (33.7) 61 (30.5)
201–350 cells/mm3 261 (32.6) 181 (30.2) 80 (40.0)
>351 cells/mm3 28 (3.5) 25 (4.2) 3 (1.5)
Baseline CD4 Count, median (IQR) 151 (70–240) 148 (61–237) 162 (87–257)
ART: antiretroviral therapy, 3TC: stavudine, TDF: tenofovir, EFV: efavirenz, NVP: nevirapine
1All the baseline characteristics were matched using propensity scores
doi:10.1371/journal.pone.0168118.t002
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Costs by site, outcome, and cost category are presented in Table 5. Drugs and diagnostic
tests are procured centrally by government and thus have identical unit costs between sites;
higher costs in these categories between sites indicate higher resource usage. Patients who
spend 12 months in care have similar drug and diagnostic costs between sites, indicating
Table 3. Outcomes at 12 months after ART initiation with relative risk.
Outcomes Total HIV Outpatient Clinic Primary Health Clinic Relative Riska
n/N (%) n/N (%) n/N (%) (95% CI)
Primary Outcome
Alive and in care 595/800 (74.4) 432/600 (72.0) 163/200 (81.5) -
Dead / LTFU 205/800 (25.6) 168/600 (28.0) 37/200 (18.5) 0.66(0.48–0.91)
100 cells/mm3 89/248 (35.9) 74/192 (38.5) 15/56 (26.8) 0.70 (0.44–1.11)
101–200 cells/mm3 61/262 (23.3) 45/201 (22.4) 7/61 (11.5) 0.51 (0.24–1.08)
201–350 cells/mm3 80/261 (30.7) 45/181 (24.9) 14/80 (17.5) 0.70 (0.41–1.21)
>351 cells/mm3 3/29 (10.3) 4/26 (15.4) 1/3 (33.3) 2.17 (0.35–13.6)
Secondary Outcome
Unsuppressed viral load* 59/238 (24.8) 36/167 (21.6) 23/71 (32.4) 1.50 (0.96–2.34)
Immunologic failure** 10/205 (4.9) 8/139 (5.8) 2/66 (3.0) 0.53 (0.12–2.41)
SENSITIVITY ANALYSIS***
Primary Outcome
Alive and in care 739/988 (75.0) 550/741 (74.2) 189/247 (76.5) -
Dead / LTFU 249/988 (25.0) 191/741 (25.8) 58/247 (23.5) 0.91 (0.71–1.18)
aRelative risk of outcome at primary health clinic, with HIV outpatient clinic as reference
* Only includes those with a viral load between 9–15 months
**Only includes those with CD4 counts between 9–15 months
***Newly matched sample including missing files
doi:10.1371/journal.pone.0168118.t003
Table 4. Time in care (months) and resource utilization for study period by outcome and facility.













Patients, n 600 200 432 163 168 37
CD4 count (cells/mm3), median 148 162 155 164 121 142
CD4 count (cells/mm3), IQR 61–237 87–257 84–242 100–258 32–214 49–255
RESOURCES USED IN STUDY PERIOD
Average months in care 9.7 11.2 12.0 12.0 3.7 7.5
Number of visits 7.0 6.6 8.7 7.3 2.7 3.5
Laboratory tests
Alanine aminotransferase 0.6 1.0 0.8 1.0 0.2 0.9
CD4 count 0.5 1.7 0.7 1.9 0.1 1.1
Creatinine 0.7 2.2 0.8 2.4 0.3 1.2
Full blood count 0.6 1.0 0.8 1.0 0.2 1.0
Viral load 0.5 0.7 0.7 0.9 0.0 0.9
Total unit cost per visit (USD*) 31 9 31 9 31 9
Staffing cost per visit (USD*) 25 8 25 8 25 8
Fixed cost per visit (USD*) 6 1 6 1 6 1
*Costs are given in 2014 US dollars, converted at a rate of R10.83 to US$1.00
doi:10.1371/journal.pone.0168118.t004
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similar resource utilization. Unit costs for staffing and fixed costs are specific to the site,
reflecting staffing composition, infrastructure, equipment, and patient volume. Differences in
these cost categories can thus reflect differences in unit costs and/or resource usage.
The average cost per patient initiated on ART over the 12 months following initiation was
significantly lower at the PHC ($213) than at the HIV outpatient clinic ($342). This finding of
lower costs at the PHC held for all outcomes and remained valid even when the longer dura-
tion of care for those ultimately not in care was taken into account: $20 v. $36 per month at the
PHC and HIV outpatient clinic, respectively, for patients in care and $13 v. $33 per month for
patients not in care. The cost per month in care was calculated by dividing the total average
cost per patient (Table 5) by the average months in care (Table 4). Most of this difference
derives from the higher costs of staff and infrastructure at the HIV outpatient clinic. While
patients at the HIV outpatient clinic made slightly more visits, the cost per visit was substan-
tially more ($31 v. $9).
Discussion
In this analysis of outcomes and costs of providing antiretroviral therapy under South Africa’s
two major models of service delivery, we found that both models achieved similar proportions
of patients alive and in care 12 months after initiation, but the primary health clinic model cost
substantially less per patient treated, despite providing more months of patient care overall.
This cost difference is due largely to the higher staff and infrastructure costs incurred in a hos-
pital-based clinic, and reflect the fact that ART patients rarely require the more specialized ser-
vices and equipment available at a hospital.
Other studies in South Africa have consistently found that decentralization to PHCs from
centralized clinics and task shifting to nurses produce favorable or equivalent results for
patients [14–16, 20, 21, 24]. We previously showed that down-referral of stable ART patients
to PHCs after initiation at a hospital-based HIV outpatient clinic reduced the costs of manag-
ing stable patient [17]. The study reported here, which demonstrated both equivalent patient
outcomes and lower costs for PHC-level, nurse-led initiation and management, stands in con-
trast to the only other cost estimate of this model we discovered, from the STRETCH trial in
South Africa’s Free State Province. The STRETCH trial found that nurse initiation and man-
agement can improve health outcomes and quality of care somewhat, but at a higher mean
cost [24, 25] that reflected high setup and implementation costs and more clinic visits per
patient in the nurse-led arm. Patients in the STRETCH trial were enrolled prior to the advent
of NIMART and were managed under the constraints of a randomized controlled trial. Our
study is therefore more likely to reflect current, actual conditions in the public sector since
Table 5. Mean 12 month cost per patient (USD) by outcome and facility, broken down by cost category.
All patients (USD) Alive in care (USD) Dead / LTFU (USD)












Drugs 85 (25%) 100 (47%) 108 (25%) 113 (47%) 28 (23%) 43 (43%)
Diagnostics 41 (12%) 51 (24%) 53 (12%) 57 (24%) 11 (9%) 24 (24%)
Staffing 177 (52%) 56 (26%) 219 (51%) 62 (26%) 68 (56%) 30 (30%)
Fixed 39 (11%) 6 (3%) 48 (11%) 7 (3%) 15 (12%) 3 (3%)
Average cost per patient
(95% CI)
342 (326, 358) 213 (204, 222) 428 (422, 452) 238 (233, 244) 122 (106, 137) 100 (87, 113)
1Costs are given in 2014 US dollars, converted at a rate of R10.83 to US$1.00
doi:10.1371/journal.pone.0168118.t005
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NIMART became the standard of care. The knowledge that PHCs can deliver equally good
care, at much lower cost, will help the South African Government, neighboring governments,
and their partners to make cost-effective decisions about program design.
Shifting ART responsibilities from doctors to nurses has occurred to varying degrees across
all treatment facilities in South Africa. At PHCs, nurses provide nearly all HIV services, with
only occasional referral, and HIV care is largely integrated with other primary health care.
HIV outpatient clinics at hospitals remain stand-alone services with relatively significant doc-
tor involvement, with NIMART trained nurses working alongside but not always replacing
doctors. We found that this staffing mix, which also affects patient volume and the efficiency
of staff time use, is one of the two main causes of the high cost of HIV outpatient clinics (the
other is simply the higher cost of hospital infrastructure). The importance of the staff comple-
ment suggests that a re-allocation of responsibilities, with complicated patients (e.g. patients
with very low CD4 counts at initiation, patients failing first line therapy, patients on second
line therapy) referred to hospital-based HIV clinics and the vast majority of uncomplicated
patients initiated and managed at PHCs. Supporting this recommendation, a study of the
NIMART rollout in the City of Johannesburg found that NIMART increased ART initiations
at PHCs and reduced them at hospital-based HIV clinics, allowing the hospital clinics to focus
on more difficult cases [22].
Although we estimated both costs and effectiveness of the two models of ART delivery, our
study was not designed as a cost-effectiveness analysis (CEA), as we do not believe that a choice
can be made between the two models. In view of the vast demand for HIV treatment in South
Africa, both models will continue to be required for years to come. The information we report
will help support efficient allocation of patients between facilities, decisions about future
expansion of treatment capacity, and planning and budgeting.
This study had a number of limitations, most of which are common to retrospective, obser-
vational cohort studies. Most important, the study was limited to a single pair of sites in one
province, which limits geographic generalizability. The study sites are, however, public sector
treatment facilities following the national treatment guidelines, and are thus likely to be typical
of the public sector in other provinces in South Africa, if not of other countries. Although we
matched our samples carefully using a rigorous matching algorithm, moreover, unobserved
differences between the samples may bias our estimates. With small samples and limited
covariates its possible that although individual patients were matched on their p-score some
residual confounding may remain. Our results are dependent on the accuracy and complete-
ness of routinely collected patient records, which may also have varied by site. Finally, despite
our access to relatively recent data, the rapid pace of change of national and global treatment
guidelines makes it nearly impossible for research to “keep up” with the current treatment
landscape.
In spite of these limitations, we conclude that initiating and managing ART patients at pri-
mary health clinics under South Africa’s NIMART policy is producing equally good outcomes
as hospital-based HIV outpatient clinic care at much lower cost. Evolution of the country’s
hospital-based clinics into well-resourced, centralized, expert referral facilities that focus on
complicated patients, while investing program expansion resources into PHCs, may thus be
the country’s preferred strategy. There are currently no widely-utilized guidelines for how to
triage patients between routine PHC care and specialized HIV clinic care. Developing guid-
ance in this area may thus be a priority for policy makers.
While our findings should support the continued expansion of NIMART, we conclude by
noting that the impact of the program on non-HIV care must also be considered. So far, nurses
appear to have incorporated HIV care into their workloads smoothly, but there is no evidence
to suggest how much additional capacity remains on the system or that the addition of HIV
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PLOS ONE | DOI:10.1371/journal.pone.0168118 December 12, 2016 9 / 12
care has not been to the detriment of other patients. While we have looked specifically at the
provider costs of ART, a full evaluation of the NIMART program—and of similar decentraliz-
ing and task-shifting initiatives in other countries—should take into account both the impact
of the program on non-HIV care and its benefits and costs to patients themselves.
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